# US 2024/0123045 A1 · Nonautologous multi-stressed cancer cells and uses thereof for vaccinating and treating cancers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0123045 A1
- Document ID: US20240123045A1
- Status: Published application
- Kind: A1
- Application number: 18/547,760
- Filed: 2022-02-25
- Published: 2024-04-18
- Earliest claimed: 2021-02-26
- Assignees: Brenus Pharma
- Applicants: Brenus Pharma
- Inventors: Benoit PINTEUR; Paul BRAVETTI
- Web page: https://patentgrep.com/patent/US20240123045A1

## CPC

- A61K 39/001176: {Heat shock proteins}
- A61P 35/00: Antineoplastic agents
- A61K 35/13: Tumour cells, irrespective of tissue of origin (tumour vaccines A61K39/00)
- A61K 35/38: Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
- A61K 39/0011: {Cancer antigens}
- C12N 5/0693: {Tumour cells; Cancer cells}
- A61K 2039/5152: {Tumor cells}
- A61K 2039/6012: {Haptens, e.g. di- or trinitrophenyl (DNP, TNP)}
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C12N 2501/06: Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
- C12N 2523/00: Culture process characterised by temperature
- C12N 2529/00: Culture process characterised by the use of electromagnetic stimulation
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Advanced therapy medicinal products (AMTPs) for cell therapy. In particular, a composition including stressed HT-29, HCT-116 and LoVo cells, and immunogenic stress proteins produced by these cells in response to stresses applied in vitro. The composition allows to simultaneously counteract multiple cell resistance mechanisms observed in situ in cancer cells, and is therefore suitable for vaccinating and treating cancers in human patients.

## Claims

### Claim at position 1

1-17. (canceled)

### Claim 18

A composition comprising (i) stressed HT-29, HCT-116 and LoVo cells, and (ii) immunogenic stress proteins produced by these cells in response to a stress applied in vitro.

### Claim 19 (depends on 18)

The composition according to claim 18, wherein stressed HT-29, HCT-116 and LoVo cells have developed resistance mechanism in response to one or several stress[es] applied in vitro, selected from the group comprising radiations, thermal stress, chemical stress, metabolic stress and any combinations thereof, leading to the production of the stress proteins.

### Claim 20 (depends on 18)

The composition according to claim 18, wherein stressed HT-29, HCT-116 and LoVo cells are non-proliferative.

### Claim 21 (depends on 18)

The composition according to claim 18, wherein immunogenic stress proteins are haptenated.

### Claim 22 (depends on 18)

The composition according to claim 18, wherein immunogenic stress proteins are haptenated with a hapten selected from the group comprising 2,4-dinitrophenyl (DNP); 2,4-dinitrofluorobenzene; sulfanilic acid; N-iodoacetyl-N′-(5-sulfonic-naphthyl)ethylene diamine; anilin; p-amino benzoic acid; biotin; fluorescein and derivatives thereof (including FITC, TAMRA, and Texas Red); digoxigenin; 5-nitro-3-pyrazolecarbamide; 4,5-dimethoxy-2-nitrocinnamide; 2-(3,4-dimethoxyphenyl)-quinoline-4-carbamide; 2,1,3-benzoxadiazole-5-carbamide; 3-hydroxy-2-quinoxalinecarbamide, 4-(dimethylamino)azobenzene-4′-sulfonamide (DABSYL); rotenone isooxazolinI(E)-2-(2-(2-oxo-2,3-dihydro-1H-benzo[b][1,4]diazepin-4-yl)phenozy)acetamide; 7-(diethylamino)-2-oxo-2H-chromene-3-carboxylic acid; 2-acetamido-4-methyl-5-thiazolesulfonamide; and p-methoxyphenylpyrazopodophyllamide.

### Claim 23 (depends on 18)

The composition according to claim 18, being a pharmaceutical composition or a vaccine composition, and further comprising at least one pharmaceutically acceptable excipient.

### Claim 24 (depends on 18)

The composition according to claim 18, comprising from about 105 to about 108 stressed HT-29, HCT-116 and LoVo cells.

### Claim 25 (depends on 18)

A method of treating cancer in a subject in need thereof, comprising administering to the subject the composition according to claim 18.

### Claim 26

An intermediate composition comprising (i) one of stressed HT-29 cells, stressed HCT-116 cells and stressed LoVo cells, and (ii) stress proteins,
wherein the one of stressed HT-29 cells, stressed HCT-116 cells or stressed LoVo cells have developed resistance mechanism in response to (i) a metabolic stress, (ii) radiations and (iii) a thermal stress applied in vitro, leading to the production of the stress proteins, or
wherein the one of stressed HT-29 cells, stressed HCT-116 cells or stressed LoVo cells have developed resistance mechanism in response to (i) a metabolic stress, and (ii) a chemical stress applied in vitro, leading to the production of the stress proteins.

### Claim 27 (depends on 26)

A method of manufacturing the intermediate compositions according to claim 26 comprising the following steps:
a) cultivating HT-29, HCT-116 or LoVo cells in a suitable culture medium;
b) subjecting the HT-29, HCT-116 or LoVo cells cultured in step a) to one or several stress[es] in vitro, wherein these HT-29, HCT-116 or LoVo cells develop resistance mechanisms in response to the one or several stress[es] and thereby produce stress proteins,
c) recovering the stressed HT-29, HCT-116 or LoVo cells together with the stress proteins they have produced in step b), and
d) treating the stressed HT-29, HCT-116 or LoVo cells and the stress proteins they have produced, all together recovered in step c), with a molecule or by a process capable of rendering the stress proteins immunogenic.

### Claim 28 (depends on 27)

The method according to claim 27, wherein step c) is carried out at least several hours after completion of step b).

### Claim 29 (depends on 27)

The method according to claim 27, wherein step d) comprises linking the stress proteins to or complexing the stress proteins with a means capable to confer immunogenicity.

### Claim 30 (depends on 29)

The method according to claim 29, wherein the means capable to confer immunogenicity is an hapten.

### Claim 31 (depends on 30)

The method according to claim 30, wherein the hapten is selected from the group comprising 2,4-dinitrophenyl (DNP); 2,4-dinitrofluorobenzene; sulfanilic acid; N-iodoacetyl-N′-(5-sulfonic-naphthyl)ethylene diamine; anilin; p-amino benzoic acid; biotin; fluorescein and derivatives thereof (including FITC, TAMRA, and Texas Red); digoxigenin; 5-nitro-3-pyrazolecarbamide; 4,5-dimethoxy-2-nitrocinnamide; 2-(3,4-dimethoxyphenyl)-quinoline-4-carbamide; 2,1,3-benzoxadiazole-5-carbamide; 3-hydroxy-2-quinoxalinecarbamide, 4-(dimethylamino)azobenzene-4′-sulfonamide (DABSYL); rotenone isooxazoline; (E)-2-(2-(2-oxo-2,3-dihydro-1H-benzo[b][1,4]diazepin-4-yl)phenozy)acetamide; 7-(diethylamino)-2-oxo-2H-chromene-3-carboxylic acid; 2-acetamido-4-methyl-5-thiazolesulfonamide; and p-methoxyphenylpyrazopodophyllamide.

### Claim 32 (depends on 27)

The method according to claim 27, wherein step b) comprises subjecting the HT-29, HCT-116 or LoVo cells cultured in step a) to the following stresses in vitro, applied concomitantly or successively:
(i) an in vitro culture in a depleted medium, under hypoxia, and/or at low pH;
(ii) an in vitro radiation with a total dose ranging from about 0.25 to about 25 Gy, for a period ranging from about 1 to about 20 minutes, and
(iii) an in vitro thermic choc at a temperature ranging from about 38° C. to about 45° C., applied to the cells for a period ranging from about 15 minutes to about 4 hours.

### Claim 33 (depends on 27)

The method according to claim 27, wherein step b) comprises subjecting the HT-29, HCT-116 or LoVo cells cultured in step a) to the following stresses in vitro, applied concomitantly or successively:
(i) an in vitro culture in a depleted medium, under hypoxia, and/or at low pH,
(ii) an in vitro exposition to at least one or several chemotherapeutic agents and/or alcohols, for a period ranging from about 6 hours to about 120 hours.

### Claim 34 (depends on 33)

The method according to claim 33, wherein:
the cells are HT-29 cells and the in vitro exposition at (ii) is to about 13 μM oxaliplatin for a period of about 72 hours; or
the cells are HCT-116 cells and the in vitro exposition at (ii) is to about 315 nM SN-38 (7-ethyl-10-hydroxy-camptothecin) for a period of about 48 hours; or
the cells are LoVo cells and the in vitro exposition at (ii) is to about 5 μM fluorouracil (5-FU) for a period of about 48 hours.

### Claim 35 (depends on 18)

A method of manufacturing the composition according to claim 18, comprising the following steps:
a) obtaining six intermediate compositions,
wherein the six intermediate compositions are:
1) an intermediate composition comprising stressed HT-29 cells and stress proteins, wherein the stressed HT-29 cells have developed resistance mechanism in response to (i) a metabolic stress, (ii) radiations and (iii) a thermal stress applied in vitro, leading to the production of the stress proteins,
2) an intermediate composition comprising stressed HCT-116 cells and stress proteins, wherein the stressed HCT-116 cells have developed resistance mechanism in response to (i) a metabolic stress, (ii) radiations and (iii) a thermal stress applied in vitro, leading to the production of the stress proteins,
3) an intermediate composition comprising stressed LoVo cells and stress proteins, wherein the stressed LoVo cells have developed resistance mechanism in response to (i) a metabolic stress, (ii) radiations and (iii) a thermal stress applied in vitro, leading to the production of the stress proteins,
4) an intermediate composition comprising stressed HT-29 cells and stress proteins, wherein the stressed HT-29 cells have developed resistance mechanism in response to (i) a metabolic stress, and (ii) a chemical stress applied in vitro, leading to the production of the stress proteins,
5) an intermediate composition comprising stressed HCT-116 cells and stress proteins, wherein the stressed HCT-116 cells have developed resistance mechanism in response to (i) a metabolic stress, and (ii) a chemical stress applied in vitro, leading to the production of the stress proteins,
6) an intermediate composition comprising stressed LoVo cells and stress proteins, wherein the stressed LoVo cells have developed resistance mechanism in response to (i) a metabolic stress, and (ii) a chemical stress applied in vitro, leading to the production of the stress proteins,
b) mixing these six intermediate compositions together.

### Claim 36 (depends on 35)

The method according to claim 35, wherein the six intermediate compositions are mixed together in an equal ratio of stressed HT-29, HCT-116 and LoVo cells.
